Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Male
Hormone Refractory Prostate Cancer, Prostate Cancer
Male
Hormone Refractory Prostate Cancer, Prostate Cancer
Trial Information
Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy
Inclusion Criteria:
- Age > or = 18 years
- Pathological diagnosis of adenocarcinoma of the prostate
- First or later line of chemotherapy
- Serum testosterone < 50ng/mL
- ECOG 0-2
- Serum PSA > or = 5ng/mL
- PSA progression (2 rises above a reference value)
- Bone scan within 60 days of enrollment
- Computed tomography (CT) scan
- If measurable disease, bone scans every 6-8 months
Exclusion Criteria:
- Systemic radiation
- Prior history of other carcinoma within the last 5 years, except non-melanoma skin
cancer
- Brain metastases
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Overall Survival
Outcome Time Frame:
Up to 36 months from time of baseline draw
Safety Issue:
No
Principal Investigator
Ken Pienta, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Michigan
Authority:
United States: Institutional Review Board
Study ID:
IMMC-38
NCT ID:
NCT00133900
Start Date:
December 2004
Completion Date:
February 2009
Related Keywords:
- Hormone Refractory Prostate Cancer
- Prostate Cancer
- hormone refractory prostate cancer
- Neoplastic Cells, Circulating
- Prostatic Neoplasms
Name | Location |
|---|---|
| Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio 44195 |
